New drug combo aims to tackle Hard-to-Treat cancers
NCT ID NCT05163041
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called BT7480, given alone or with another drug (nivolumab), in 200 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shrinks tumors. It is an early-stage trial, so results will show if further testing is worthwhile.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BT7480 (a drug given by IV) and nivolumab (an immunotherapy drug)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 200 participants, so the drug may not prove effective or safe enough for wider use. Side effects are unknown and could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
START Center for Cancer Care
San Antonio, Texas, 78229, United States
-
State University of Iowa
Iowa City, Iowa, 52242, United States
-
The Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, SM2 5PT, United Kingdom
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States